Literature DB >> 16682836

Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels.

C Otto1, B Otto, B Göke, A F H Pfeiffer, M Lehrke, M Vogeser, J Spranger, K G Parhofer.   

Abstract

Glitazones increase the secretion of the adipocyte-derived hormone adiponectin. Furthermore, the gastric signal peptide ghrelin is known to suppress adiponectin expression in adipocyte cell culture models. It is not known whether the increase in adiponectin during glitazone therapy is due to a suppression of ghrelin levels, a decrease of resistin concentrations or an amelioration of glucose control. In 10 patients (age 71+/-9 yr, body mass index 29.9+/-3.6 kg/m(2), HbA1c 6.9+/-0.5%) with Type 2 diabetes, who had already been treated with sulfonylureas, we additionally initiated a pioglitazone therapy (30 mg/day) for 12 weeks. To investigate the pioglitazone effect independently of blood glucose, glycosylated hemoglobin (HbA1c) was kept unchanged by reducing the daily dose of sulfonylurea if necessary. Ghrelin concentration [radioimmunoassay (RIA), Phoenix Pharmaceuticals, Mountain View, CA, USA], adiponectin levels [enzyme-linked immunosorbent assay (ELISA), Biovendor, Heidelberg, Germany] as well as resistin concentrations (ELISA, Linco Research, St. Charles, MO, USA) were measured before and after pioglitazone. Glucose control remained unchanged within the 12-week pioglitazone therapy (HbA1c 6.9+/-0.5% before vs 6.8+/-0.6% after pioglitazone) while body weight increased from 86.6+/-9.2 to 88.0+/-9.4 kg (p<0.05), and insulin concentration decreased from 19.6+/-5.7 to 10.1+/-1.6 microU/ml (p<0.05). Adiponectin concentration increased in all patients from 7.70+/-2.47 to 23.33+/-8.28 microg/ml (p<0.01), while resistin concentrations tended to decrease (by 15%; p=0.059). However, ghrelin remained unchanged during therapy. No correlations were observed either between ghrelin, resistin, insulin and adiponectin, or between body weight and hormone plasma levels. The increase in adiponectin levels during pioglitazone therapy seems to be at least partly independent of blood glucose and insulin concentration as well as of ghrelin levels, and it was not associated with a decrease in resistin concentrations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682836     DOI: 10.1007/BF03345545

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  28 in total

1.  Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 -- results of a pilot study.

Authors:  K G Parhofer; C Otto; H C Geiss; E Laubach; B Göke
Journal:  Exp Clin Endocrinol Diabetes       Date:  2005-01       Impact factor: 2.949

2.  Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes.

Authors:  Mathias Fasshauer; Johannes Klein; Susanne Neumann; Markus Eszlinger; Ralf Paschke
Journal:  Biochem Biophys Res Commun       Date:  2002-01-25       Impact factor: 3.575

3.  Insulin decreases human adiponectin plasma levels.

Authors:  M Möhlig; U Wegewitz; M Osterhoff; F Isken; M Ristow; A F H Pfeiffer; J Spranger
Journal:  Horm Metab Res       Date:  2002 Nov-Dec       Impact factor: 2.936

4.  Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma.

Authors:  Y Nakano; T Tobe; N H Choi-Miura; T Mazda; M Tomita
Journal:  J Biochem       Date:  1996-10       Impact factor: 3.387

5.  Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes.

Authors:  Seppo M Pöykkö; Eija Kellokoski; Sohvi Hörkkö; Heikki Kauma; Y Antero Kesäniemi; Olavi Ukkola
Journal:  Diabetes       Date:  2003-10       Impact factor: 9.461

6.  Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans.

Authors:  Jonathan Q Purnell; David S Weigle; Patricia Breen; David E Cummings
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

7.  Adiponectin and protection against type 2 diabetes mellitus.

Authors:  Joachim Spranger; Anja Kroke; Matthias Möhlig; Manuela M Bergmann; Michael Ristow; Heiner Boeing; Andreas F H Pfeiffer
Journal:  Lancet       Date:  2003-01-18       Impact factor: 79.321

8.  The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.

Authors:  Joseph G Yu; Sandrine Javorschi; Andrea L Hevener; Yolanta T Kruszynska; Rodney A Norman; Madhur Sinha; Jerrold M Olefsky
Journal:  Diabetes       Date:  2002-10       Impact factor: 9.461

9.  Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity.

Authors:  Utpal B Pajvani; Meredith Hawkins; Terry P Combs; Michael W Rajala; Tom Doebber; Joel P Berger; John A Wagner; Margaret Wu; Annemie Knopps; Anny H Xiang; Kristina M Utzschneider; Steven E Kahn; Jerrold M Olefsky; Thomas A Buchanan; Philipp E Scherer
Journal:  J Biol Chem       Date:  2003-12-29       Impact factor: 5.157

10.  Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes.

Authors:  Julia Tonelli; Weijie Li; Preeti Kishore; Utpal B Pajvani; Elize Kwon; Charles Weaver; Philipp E Scherer; Meredith Hawkins
Journal:  Diabetes       Date:  2004-06       Impact factor: 9.461

View more
  7 in total

1.  Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.

Authors:  Petra B Musholt; Thomas Schöndorf; Andreas Pfützner; Cloth Hohberg; Iris Kleine; Winfried Fuchs; Silvia Hehenwarter; Gerhard Dikta; Benedikt Kerschgens; Thomas Forst
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

2.  Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis.

Authors:  M Kawaguchi-Suzuki; F Bril; S Kalavalapalli; K Cusi; R F Frye
Journal:  Aliment Pharmacol Ther       Date:  2017-05-03       Impact factor: 8.171

3.  A lower serum level of middle-molecular-weight adiponectin is a risk factor for endometrial cancer.

Authors:  Yukari Ohbuchi; Yasunobu Suzuki; Ikuo Hatakeyama; Yoshifumi Nakao; Atsuya Fujito; Tsuyoshi Iwasaka; Keiichi Isaka
Journal:  Int J Clin Oncol       Date:  2013-08-22       Impact factor: 3.402

4.  Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Miina K Ohman; Yuechun Shen; Chinyere I Obimba; Andrew P Wright; Mark Warnock; Daniel A Lawrence; Daniel T Eitzman
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

5.  The expression of resistin in adipose tissues of patients with polycystic ovary syndrome and insulin resistance.

Authors:  Yongli Chu; Qing Cui; Guijiao Feng; Zhiyun Song; Xueqiang Jiang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-10-11

6.  Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial.

Authors:  Atsushi Tanaka; Sho Komukai; Yoshisato Shibata; Hiroyoshi Yokoi; Yoshihiro Iwasaki; Tomohiro Kawasaki; Kenji Horiuchi; Koichi Nakao; Takafumi Ueno; Hitoshi Nakashima; Masahiro Tamashiro; Yutaka Hikichi; Mitsuhiro Shimomura; Motoko Tago; Shigeru Toyoda; Teruo Inoue; Atsushi Kawaguchi; Koichi Node
Journal:  Heart Vessels       Date:  2018-02-27       Impact factor: 2.037

7.  PPAR Gamma: Coordinating Metabolic and Immune Contributions to Female Fertility.

Authors:  Cadence E Minge; Rebecca L Robker; Robert J Norman
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.